{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '27. NCT02136134. Addition of daratumumab to combination of bortezomib and', 'dexamethasone in participants with relapsed or refractory multiple myeloma -sponsored', 'by Janssen Research & Development, LLC. Available from:', 'https://clinicaltrials.gov/ct2/show/NCT02136134', '28. NCT02199665. Selinexor, carfilzomib, and dexamethasone in treating patients with', 'relapsed or refractory multiple myeloma (SINE) -sponsored by the University of', 'Chicago. Available from: https://clinicaltrials.gov/ct2/show/NCT02199665', '29. NCT02343042. Selinexor and backbone treatments of multiple myeloma patients', '(STOMP) -sponsored by Karyopharm. Available from:', 'https://clinicaltrials.gov/ct2/show/NCT02343042.', '30. NCT02755597. A study evaluating venetoclax (ABT-199) in multiple myeloma subjects', 'who are receiving bortezomib and dexamethasone as standard therapy -sponsored by', 'AbbVie. Available from: https://clinicaltrials.gov/ct2/show/NCT02755597.', '31. Neggers JE, Vanstreels E, Baloglu E, et al. Heterozygous mutation of cysteine528 in', 'XPO1 is sufficient for resistance to selective inhibitors of nuclear export. Oncotarget.', '2016.', '32. Neggers JE, Vercruysse T, Jacquemyn M, Vanstreels E, Baloglu E, Shacham S, et al.', 'Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by', 'CRISPR/Cas9 genome editing. Chem Biol. 2015;22:107-16.', \"33. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics.\", '1979;35(3):549-56.', '34. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern', 'Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-55.', '35. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for', 'Multiple Myeloma: A Report From International Myeloma Working Group. J Clin', 'Oncol. 2015;33(26):2863-9.', '36. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and', 'Dexamethasone for Multiple Myeloma. N. Eng. J. Med. 2016;375(8):754-66.', '37. Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N. Eng.', 'J. Med. 2011;365(5):474-5.', '38. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a novel CRM1 inhibitor in acute', 'myeloid leukemia. Blood. 2012;120(9):1765-73.', '39. Reece DE, Sullivan D, Lonial S, et al. Pharmacokinetic and pharmacodynamic study of', 'two doses of bortezomib in patients with relapsed multiple myeloma. Cancer Chemother.', 'Pharmacol. 2011;67(1):57-67.', '40. Reeder CB, Reece DE, Kukreti V, et al. Once- versus twice-weekly bortezomib induction', 'therapy with CyBorD in newly diagnosed multiple myeloma. Blood. 2010;115(16):3416-', '7.', '41. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed,', 'refractory myeloma. N. Eng. J. Med. 2003;348(26):2609-17', 'Confidential', 'Page 110', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '42. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose', 'dexamethasone for relapsed multiple myeloma. N. Eng. J. Med. 2005;352(24):2487-98.', '43. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in', 'relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood.', '2007;110(10):3557-60.', '44. Rosebeck S, Alonge MM, Kandarpa M, et al. Synergistic Myeloma Cell Death via Novel', 'Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and', 'Selinexor. Mol Cancer Ther. 2016;15(1):60-71.', '45. Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell', 'cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms', 'and therapeutic implications. Leukemia. 2014;28(1): 155-65.', '46. Turner JG, Dawson J, Emmons MF, et al. CRM1 Inhibition sensitizes drug resistant', 'human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex', 'vivo. Journal of Cancer. 2013;4(8):614-25.', '47. Turner JG, Kashyap T, Dawson JL, et al. XPO1 inhibitor combination therapy with', 'bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes', 'acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget. 2016.', '48. Velcade [bortezomib] Prescribing Information. Velcade (bortezomib) Prescribing', 'Information, USA. Available from:', 'http://www.velcade.com/files/pdfs/velcade_prescribing_information.pdf.', '49. Wu T, Chen W, Zhong Y, et al. Nuclear export of ubiquitinated proteins determines the', 'sensitivity of colorectal cancer to proteasome inhibitor. Mol Cancer Ther. 2016.', '50. Zhang K, Wang M, Tamayo AT, et al. Novel selective inhibitors of nuclear export CRM1', 'antagonists for therapy in mantle cell lymphoma. Exp Hematol. 2013;41(1):67-78 e e4.', 'Confidential', 'Page 111', 'Version 4.0']\n\n###\n\n", "completion": "END"}